Trial Profile
A Multicenter, Retrospective Study Assessing the Efficacy and Safety of Off-Label Secukinumab Dose Escalation in the Treatment of Moderate-to-Severe Psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism.